콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

A3650

Sigma-Aldrich

Amikacin hydrate

aminoglycoside antibiotic

동의어(들):

N1-[(S)-4-Amino-2-hydroxybutyryl]kanamycin A

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C22H43N5O13 · xH2O
CAS Number:
1257517-67-1
Molecular Weight:
585.60 (anhydrous basis)
Beilstein:
1445422
EC Number:
253-538-5
MDL number:
MFCD11045969
UNSPSC 코드:
51281632
PubChem Substance ID:
24890796
NACRES:
NA.85

생물학적 소스

synthetic

Quality Level

200

형태

powder

색상

white to almost white

항생제 활성 스펙트럼

Gram-negative bacteria
mycobacteria

동작 모드

protein synthesis | interferes

저장 온도

2-8°C

SMILES string

O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O

InChI

1S/C22H43N5O13.H2O/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);1H2/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;/m0./s1

InChI key

DTSOZYYWEZJFSS-XTHCGPPUSA-N

일반 설명

Chemical structure: aminoglycoside

애플리케이션

Amikacin hydrate is used in antimicrobial susceptibility studies of organisms such as Mycobacterium tuberculosis and Ehrlichia phagocytophila.

생화학적/생리학적 작용

Amikacin inhibits bacterial protein synthesis by binding to the 30S ribosome subunit and inducing mRNA misreading. It interferes with the translocation of tRNA from the A-site to the P-site.

포장

5G

기타 정보

Keep container tightly closed in a dry and well-ventilated place.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

Eyeshields, Gloves, type N95 (US)

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

G J Alangaden et al.
Antimicrobial agents and chemotherapy, 42(5), 1295-1297 (1998-05-21)
An A1400G mutation of the rrs gene was identified in Mycobacterium tuberculosis (MTB) strain ATCC 35827 and in 13 MTB clinical isolates resistant to amikacin-kanamycin (MICs, >128 microg/ml). High-level cross-resistance may result from such a mutation since MTB has a
H W Horowitz et al.
Antimicrobial agents and chemotherapy, 45(3), 786-788 (2001-02-22)
Human granulocytic ehrlichiosis is a recently described disease caused by an obligate intracellular gram-negative organism recently named Ehrlichia phagocytophila. To expand our knowledge of the susceptibility of E. phagocytophila, we tested six New York State isolates for susceptibility to 12
M P Goren et al.
The Pediatric infectious disease journal, 8(5), 278-282 (1989-05-01)
A three-drug antibiotic regimen including vancomycin and amikacin has been recommended as effective treatment in clinical settings in which Gram-positive bacteremias are a serious problem. To determine if vancomycin potentiates the tubular proteinuria associated with amikacin therapy, we studied febrile
P Van der Auwera
The Journal of antimicrobial chemotherapy, 27 Suppl C, 63-71 (1991-05-01)
The pharmacokinetic parameters of amikacin given once daily were compared to those of amikacin given bd at different daily dosages. In adult patients, 'peak' serum concentrations (30 min after 30 min infusion) were linearly proportional to the dose given with
Hessel Van der Weide et al.
Antibiotics (Basel, Switzerland), 9(3) (2020-03-07)
Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a "drug of last resort" warrant further research into the use of this regimen for the treatment of severe multidrug-resistant, Gram-negative bacterial infections. In the current study
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.